Keywords
How to Cite
Abstract
Aim: Evaluation of changes that have occurred in the ideas in endometrial cancer over the past 10-20 years and their potential applications.
Materials and methods: Analysis of modern publications including databases of PubMed and Russian scientific electronic library (http://elibrary.ru) with the use of the information received as a result of own studies.
Conclusions: A shifts in the incidence of endometrial cancer, a reform of the views on molecular-biological typing of this tumor, changes in the ratio of its morphological variants as well as in the risk and anti-risk factors were discussed. According to our own data in a group of 144 endometrial carcinomas (endometrioid and non-endometrioid) the frequency of POLEe mutations was equal to 2.8% that might change after increasing of the number of patients. Rapidly accumulating information in this field can be useful for improving approaches to preventing and treatment of endometrial carcinoma.
References
Sheikh MA, Althouse AD, Freese KE et al. USA endometrial cancer projections to 2030: should we be con cerned? Future Oncology. 2014 Dec. 10(16), 2561-2568. DOI: 10.2217/fon.14.192
Мерабишвили ВМ, Бахидзе ЕВ, Лалианци ЭИ и др. Распространенность гинекологического рака и выживаемость больных. Вопросы онкологии. 2014; 60(3): 288-297 (Merabishvili VM, Bakhidze EV, Laliantsy EI et al. Prevalence of gynecological cancer and survival of patients. Vopr. Onkol. 2014; 60(3):228-297).
Evans T, Sany O, Pearmain P et al. Differential trends in the rising incidence of endometrial cancer by type: data from a UK population-based registry from 1994 to 2006. Br. J. Cancer. 2011 Apr 26.104(9), 1505-1510. DOI: 10.1038/bjc.2011.68
McAlpine JN, Temkin SM, Mackay HJ. Endometrial cancer: Not your grandmother’s Cancer. Cancer. 2016 Sep 15;122(18):2787-2798. DOI: 10.1002/cncr.30094
Берштейн ЛМ, Берлев ИВ, Васильев ДА и др. Ожирение и особенности рака эндометрия: меняется ли что-нибудь с годами. Вопросы онкологии. 2015; 61(4): 575-579 (Berstein LM, Berlev IV, Vasiliev DA et al. Obesity and characteristic features of endometrial cancer; are there any changesin the duration of several decades. Vopr. Onkol. 2015; 61(4): 575-579).
Балтрукова АН, Берлев ИВ, Берштейн ЛМ. Сравнительная оценка гормонально-метаболического статуса больных раком эндометрия за последние пять десятилетий. Журнал акушерства и женских болезней. 2016; LXV(1): 9-16 (Baltrukova AN, Berlev IV, Berstein LM. Comparative evaluation of hormonal-metabolic status of endometrial cancer patients over the past five decades. Journal of Obstetrics and Women’s Diseases (Russ) 2016; 65(1): 9-16).
Балтрукова Ан, Берштейн ЛМ, Берлев ИВ. Сдвиги в менструальной и репродуктивной функции у больных раком эндометрия за последние 50 лет. Вестник Северо-Западного государственного медицинского университета им. И. И. Мечникова. 2016; 8(4): 75 - 80 (Baltrukova AN, Berstein LM, Berlev IV. Changes in menstrual and reproductive function in patients with endometrial cancer over the last 50 years. Herald of the Northwestern State Medical University named after I.I. Mechnikov (Russ). 2016; 8(4): 75-80).
Балтрукова АН, Берштейн ЛМ, Берлев ИВ, Туркевич ЕА. динамика клинико-морфологических особенностей рака эндометрия за последние полвека. Вопросы онкологии. 2017; 63( 3): 428-434 (Baltrukova AN, Berstein LM, Berlev IV, Turkevich EA. Changes in endometrial cancer clinical and morphological features during the past half century. Vopr.Onkol. (Russ). 2017; 63(3): 428-434).
Рак эндометрия. Под ред. И. В. Берлева, Л. М. Берштейна, А. Ф. Урманчеевой. - Санкт-Петербург: Эко-Вектор, 2017. - 260с. 978-5-906648-40-2 (Endometrial cancer /Eds. Berlev IV, Berstein LM, Ourmantcheeva AF/, Spb.: Eco-Vector Publ., 2017, 260 pp.). ISBN: 9785906648402
Максимов С.Я., Хаджимба А.В., Вышинская ЕА и др. Рак органов репродуктивной системы в молодом возрасте. Практическая онкология. 2017; 18(2): 185196 (Maximov SYa, Hadgimba AV, Vyshynskaya EA et al. Cancer of female reproductive system in young age. Practical Oncology. 2017; 18(2): 185-196).
Sturgeon SR, Sherman ME, Kurman RJ et al. Analysis of histopathological features of endometrioid uterine carcinomas and epidemiologic risk factors. Cancer Epidemiol. Bio-markers Prev. 1998 Mar; 7(3): 231-235. PMID: 9521439.
Setiawan VW, Yang HP, Pike MC et al. Type I and II endometrial cancers: have they different risk factors? J. Clin. Oncol. 2013 July; 31(20), 2607-2018. 10.1200/ JCO.2012.48.2596. DOI: 10.1200/JCO.2012.48.2596
Самсонова ЕА, Максимова НА, Урманчеева АФ, Пожарисский КМ. Экспрессия рецепторов эстрогенов, прогестерона и онкобелка HER2 как показателя клинического течения и исхода эндометриоидной аденокарциномы тела матки. Вопросы онкологии. 2004; 50(2): 196-201 (Samsonova EA, Maximova NA, Ourmantcheeva AF, Pozharisski KM. Expression of estrogen and progesterone receptors and oncoprotein HER2 as the marker of endometrioid cancer clinical outcomes. Vopr. Onkol. (Russ). 2004; 50(2): 196-201).
Zhang Y, Zhao D, Gong C et al. Prognostic role of hormone receptors in endometrial cancer: a systematic review and meta-analysis. World J. Surg. Oncol. 2015 June 25; 13: 208. DOI: 10.1186/s12957-015-0619-1
Wolfson AH, Sightler SE, Markoe AM et al. The prognostic significance of surgical staging for carcinoma of the endometrium. Gynecol. Oncol. 1992 May; 45(2):142-146. PMID 1592280.
Joehlin-Price AS, Perrino CM, Stephens J et al. Mismatch repair protein expression in 1049 endometrial carcinomas, associations with body mass index, and other clinicopathologic variables. Gynecol. Oncol. 2014 Apr; 133(1): 43-47. DOI: 10.1016/j.ygyno.2014.01.017
Berstein LM, Poroshina TE, Turkevich EA et al. Features of endometrial cancer in patients with ‘metabolically healthy’ versus ‘standard’ obesity: the decreasing frequency of metabolically healthy obesity. Future Sci. OA. 2015 Nov 1; 1(4): FSO68.
Elwood JM, Cole P, Rothman KJ, Kaplan SD. Epidemiology of endometrial cancer. J. Natl. Cancer Inst. 1977 Oct; 59(4): 1055-1060. PMID 333120.
Aune D, Navarro Rosenblatt DA, Chan DSM et al. Anthropometric factors and endometrial cancer risk: a systematic review and dose-response meta-analysis of prospective studies. Ann Oncol. 2015 Aug; 26(8): 1635-1648. DOI: 10.1093/annonc/mdv142
Wynder EL, Escher GC, Mantel N. An epidemiological investigation of cancer of the endometrium. Cancer. 1966 Apr; 19(4): 489-520. PMID 5933575.
Liao C, Zhang D, Mungo C et al. Is diabetes mellitus associated with increased incidence and disease-specific mortality in endometrial cancer? A systematic review and meta-analysis of cohort studies. Gynecol. Oncol. 2014; 135(1): 163-171.
Бохман ЯВ. Рак тела матки. Кишинев: Штиинца. 1972, 202с. (Bokhman JV. Uterine Body Cancer. Kishinev: Shtiintsa, 1972, 202pp.).
Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol. Oncol. 1983 Feb; 15(1): 10-17. PMID 6822361.
Dallal CM, Lacey JV Jr, Pfeiffer RM et al. Estrogen Metabolism and Risk of Postmenopausal Endometrial and Ovarian Cancer: the B 0 FIT Cohort. Horm. Cancer 2016 Feb; 7(1): 49-64. DOI: 10.1007/s12672-015-0237-y
Yang HP, Cook LS, Weiderpass E et al. Infertility and incident endometrial cancer risk: a pooled analysis from the epidemiology of endometrial cancer consortium (E2C2). Cancer Epidemiol. Biomarkers Prev. 2016; 25(7): 1081-1089.
Scrivo R., Vasile M., Bartosiewicz I., Valesini G. Inflammation as "common soil" of the multifactorial diseases. Autoimmun. Revs. 2011; 10, 369-374 (2011).
Берштейн ЛМ. Роль воспалительных и противовоспалительных факторов при раке эндометрия и его типах: опухолевая и жировая ткань. Вопросы онкологии. 2016; 62(6): 732-739 (Berstein LM. The role of inflammatory and antinflammatory factors in endometrial cancer and its types: tumor and adipose tissue. Vopr. Onkol. (Rus.) 2016; 62(6): 732-739).
Kandoth C, Schultz N, Cherniack AD et al. for the Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma. Nature. 2013 May; 497(7447): 67-73. DOI: 10.1038/nature12113
Murali R, Soslow RA, Weigelt B. Classification of endometrial carcinoma: more than two types. Lancet Oncol. 2014 Jun; 15(7): e268-e278. DOI: 10.1016/S1470-2045(13)70591-6
Suarez AA, Felix AS, Cohn DE. Bokhman Redux: Endometrial cancer "types" in the 21st century. Gynecol. Oncol. 2017 Feb; 144(2): 243-249. DOI: 10.1016/j.ygyno.2016
Berthelsen H, Svane H. Cancer of the endometrium and hyperestrinism; two different modes of origin of endometrial cancer. Dan. Med. Bull. 1956 Dec; 3(8): 236-239. PMID 13384057.
Gusberg SB. Hormone-dependence of endometrial cancer. Obstet. Gynecol. 1967 Aug; 30(2): 287-293. PMID 5212339.
Dilman VM, Berstein LM, Bobrov YF, Bohman YV et al. Hypothalamopituitary hyperactivity and endometrial carcinoma. Qualitative and quantitative disturbances in hormone production. Am. J Obstet Gynecol. 1968 Nov; 102(6): 880-889. PMID: 5686906.
Берштейн ЛМ. Экскреция классических эстрогенов и суммарных фенолстероидов у больных раком тела матки. Дисс. канд. мед. наук. Л., 1967, 250 сс. (Bershtein LM. Excretion of classical estrogens and total phenolsteroids in endometrial cancer patients [PhD/Cand. Med. Sci. Dissertation]. Leningrad, 1967, 250 pp).
Lax SF, Kurman RJ. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses. Verh. Dtsch. Ges. Pathol. 1997; 81:228-232. PMID 9474874.
Sherman ME. Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod. Pathol. 2000 Mar; 13, 295-308. DOI: 10.1038/modpathol.3880051
McCourt CK, Mutch DG, Gibb RK. Body mass index: relationship to clinical, pathologic and features of microsatellite instability in endometrial cancer. Gynecol. Oncol. 2007 Mar; 104(3): 535-539. DOI: 10.1016/j.ygyno.2006.09.019
Voss MA, Ganesan R, Ludeman L et al. Should grade
endometrioid endometrial carcinoma be considered a type 2 cancer - a clinical and pathological evaluation. Gynecol. Oncol. 2012 Jan; 124: 15-20. 10.1016/j. ygyno.2011.07.030. DOI: 10.1016/j.ygyno.2011.07.030
Bellone S, Bignotti E, Lonardi S et al. Polymerase є (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro. Gynecol Oncol. 2017 Jan; 144(1): 146-152. PMID: 27894751.
Gargiulo P, Della Pepa C, Berardi S et al. Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated Endometrial Cancers: New candidates for checkpoint blockade immunotherapy? Cancer Treat. Rev. 2016 Jul;48:61-68.
Mittica G, Ghisoni E, Giannone G et al. Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity. Oncotarget. 2017 Aug 8; 8(52): 90532-90544. DOI: 10.18632/oncotarget.20042
Berstein LM. Renovated (nondual) approach to endometrial cancer typing: endocrine and inflammatory issues. Future Oncol. 2017 Jan; 13(2): 109-112.
Talhouk A, McConechy MK, Leung S et al. Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial Cancer. Cancer. 2017 Mar; 123(5): 802813 (2017). DOI: 10.1002/cncr.30496
Van Gool IC, Ubachs JEH, Stelloo E. et al. Blinded histopathological characterisation of POLE exonuclease domain-mutant endometrial cancers: sheep in wolf's clothing. Histopathology. 2018 Jan;72(2):248-258. DOI: 10.1111/his.13338
Hüsing A., Dossus L., Ferrari P. et al. An epidemiological model for prediction of endometrial cancer risk in Europe. Eur. J. Epidemiol. 2016 Jan; 31(1): 51-60. 10.1007/ s10654-015-0030-9. DOI: 10.1007/s10654-015-0030-9
Berstein LM. Modern approach to metabolic rehabilitation of cancer patients: biguanides (phenformin and metformin) and beyond. Future Oncol. 2010 Aug; 6(8): 13131323. DOI: 10.2217/fon.10.87
Чернышова А.Л., Коломиец Л.А., Саприна ТВ. и др. Современные методы корреции метаболического синдрома у больных с гиперпластическими процессами и раком эндометрия. Сибирский онкологический журнал. 2016; 15(5): 73-81 (Tchernyshova AL, Kolomiets LA, Saprina TV et al. Modern approaches to correction of metabolic syndrome in patients with endometrial hyperplasia and cancer. Siberian Cancer Journal. 2016; 15(5): 7381). DOI: 10.21294/1814-4861-2016-15-5-73-81
Luo J, Chlebowski RT, Hendryx M. et al. Intentional Weight Loss and Endometrial Cancer Risk. J. Clin. Oncol. 2017 Apr; 35(11): 1189-1193. DOI: 10.1200/J?.2016.70.5822
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2018